Dr ZHOU Lihan, Co-Founder and CEO of Mirxes
Singapore-headquartered RNA technology company, Mirxes Holding, has completed its Series D funding round, securing US$50 million.
The round is anchored by existing and new investors, including Beijing Fupu, EDBI, Mitsui & Co., NHH Venture Fund, and the Agency for Science, Technology and Research.
Mirxes Holding will use the capital to scale the adoption and penetration of its stomach cancer blood test, GASTROClear, in major Asia-Pacific markets, including Southeast Asia, China, and Japan.
Also Read: Harnessing the power of AI to help improve gastric cancer detection
A portion of the funds will be used to accelerate the development and commercialisation of Mirxes’s maturing clinical pipeline, including a blood-based colorectal cancer screening test and the multi-cancer early detection test under Project CADENCE. Project CADENCE is a project to develop a single blood test for the early detection of nine high-mortality cancers powered by the company’s RNA technology and other complementary biomarker technologies.
“This fresh funding will fuel our ambitious growth plans and enable us to continue making a significant impact in the field of multi-cancer early detection,” said Dr ZHOU Lihan, Co-Founder and CEO of Mirxes.
Along with this, Mirxes has also announced that it has filed the listing application with The Stock Exchange of Hong Kong Limited (HKEX).
Founded in 2014, Mirxes is an RNA technology company making cancer early detection solutions accessible globally. It also delivers research and clinical testing services for preventive healthcare and precision medicine to key markets in Asia and beyond.
In 2021, Mirxes raised US$77 million in a Series C financing round led by CR-CP Life Science Fund and joined by global healthcare investment firm Rock Springs Capital, Charoen Pokphand Group (Thailand) and EDBI.
—
The post Mirxes lands US$50M to take its cancer early detection solutions to new markets appeared first on e27.